Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

May 31, 2011

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

AZD1152

Variable dose via a 7-day continuous infusion

DRUG

LDAC (low dose cytosine arabinoside)

20 mg subcutaneous injection given twice daily

Trial Locations (4)

Research Site, Cleveland

Research Site, Houston

Research Site, Le Chesnay

Research Site, Villejuif